CureVac Granted Patent Claiming the Combination of mRNA Vaccines with Anti-PD-L1 Antibodies
PD-L1 Pathway Now Covered as New Patent Complements the mRNA/Anti-PD-1 Antibodies Combination Patent Granted in July 2017
CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today it has been granted a patent from the European Patent Office entitled, “Combination of Vaccination and Inhibition of the PD-1 Pathway” (EP 3292873).